Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm


Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (Nasdaq: AVTE) investors that a class action has been filed on behalf of investors. Aerovate investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Shares of Aerovate Therapeutics are down 90.1% following the release of poor top line results from its Phase 2b portion of IMPAHCT evaluating AV-101 for the treatment of pulmonary arterial hypertension. Block & Leviton is investigating whether the Company violated any securities laws in the lead up to this announcement.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising